Mosquitoes beware – your next meal could be your last
Nitisinone is already used to slow the effects of tyrosinemia type 1, a hereditary condition that can cause severe liver disease and kidney failure, and other diseases.
But it also makes any mosquitoes that ingest it unable to digest the blood they feed on, killing them rapidly, research led by the Liverpool School of Tropical Medicine (LSTM) found.
The study, published in Science Translational Medicine this week, showed that the drug blocks an essential enzyme mosquitoes need to break down their food.
Tests showed a small amount of the drug was even able to kill mosquitoes that have developed the ability to resist conventional insecticides – an increasingly widespread problem that has slowed efforts to combat malaria and other mosquito-borne diseases.
'What makes nitisinone so exciting is its novel mode of action against blood-feeding insects like mosquitoes,' said Dr Lee Haines, an Honorary Fellow at LSTM and one of the authors of the study.
'Unlike conventional insecticides that target the mosquito's nervous system, nitisinone targets an entirely different biological pathway in mosquitoes, which offers a new option for managing the growing problem of insecticide resistance.'
The study followed earlier research which first validated the theory that nitisinone could be used to kill insects that feed on blood. It proved highly effective at killing tsetse flies that spread sleeping sickness.
While the drug does not prevent a feeding mosquito from infecting someone with a virus, it could provide a new tool to combat the spread of disease by thinning out their populations, the researchers believe.
Several insecticides are already widely used in this way, such as ivermectin, a medicine usually used to treat parasitic infections in animals and people and which shortens the lifespan of any insect that ingests it.
But ivermectin, while abundant, is toxic in the environment and insects can also develop resistance to it when it is overused.
'Billions of doses have been given to people for the worming campaigns,' said Professor Álvaro Acosta Serrano, another of the study's co-authors. 'Ivermectin is obviously a very popular veterinary drug, so in farms it is polluting the soil and that has some ecological issues.'
As well as being much less harmful to other insects or animals in the ecosystem, nitisinone has the added advantage of lasting much longer in the body, he told The Telegraph.
'Nitisinone, because it has a much longer half life in blood – 54 hours compared to Ivermectin which is only 18 hours max – it has much better performance.'
As well as helping to suppress mosquito populations by killing those that unwittingly feed on humans carrying nitisinone, the drug could be used against mosquitoes in numerous other applications.
It could be used in the sugar-based bait traps currently being tested around the world which lure in mosquitoes and poison them, or it could be sprayed on to bed netting and buildings to get into mosquitoes that way.
The researchers are already planning to investigate whether the drug could be given to cows and other livestock animals to turn them into unwitting reservoirs of death for the insects that feed on them.
'This is a very versatile molecule,' Prof Acosta Serrano said.
Because it was originally developed to be a herbicide, it has many properties that make it ideal for use in these kinds of applications, including good resistance to UV light, he added.
Before all this though the researchers say more work is needed, including safety studies looking at different dosages. They are also yet to study how the drug interacts with antimalarials.
Another major challenge is cost.
While ivermectin has been produced cheaply by generic drug manufacturers for decades and has been donated in vast quantities to tackle diseases like river blindness, nitisinone – despite being off-patent – remains expensive.
'We need to convince a company to drop the prices because, for vector control use, interventions have to be really cost effective,' said Prof Acosta Serrano.
And while nitisinone promises to provide another tool with which to combat mosquito-borne disease, we are still waiting for scientific breakthroughs before we will be able to beat malaria.
'It's important to know that there is not a silver bullet to control any of the vector borne diseases, especially malaria,' he said. 'We still need to come out with better drugs. There is a huge problem with parasites that become drug resistant. We still don't have a completely efficacious vaccine available.'
Protect yourself and your family by learning more about Global Health Security
Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
6 hours ago
- Associated Press
Silicon Worms takes off: mAInthink.ai develops DeepAnT Performance, the world's fastest multivariate anomaly detection system
Worms is becoming a hotspot for predictive high-end algorithm development: The deep-tech company presents DeepAnT Performance, currently the most powerful method for anomaly detection in multivariate time series – faster and more precise than any previous solution on the market. Under the scientific direction of Dr. Igor Kadoshchuk, one of the leading minds in the field of machine learning, the mAInthink team in Worms has developed a system that sets standards:DeepAnT Performanceis based on advanced deep learning architecture and combines the highest detection accuracy with maximum processing speed. Designed for highly complex data environments DeepAnT unfolds its full potential especially in data-intensive sectors such as finance for example: Convincing numbers: DeepAnT dominates all benchmarks In extensive comparative tests, DeepAnT Performance was tested against the most well-known methods on the market - including ARIMA, LSTM, Isolation Forest and rPCA. Test setup: Results (see graphic): 'With DeepAnT Performance, we demonstrate that cutting-edge AI doesn't have to come exclusively from Silicon Valley. Our solution was developed in Worms, the city of the Nibelungs, by an interdisciplinary team with global ambitions. We believe that precision, speed, and scalability, as well as the ability to predict specific processes to be monitored, are the new currency in the fight against anomalies, fraud, and system instabilities. DeepAnT Performance is our answer to this challenge—technologically superior, economically relevant, and ready for immediate deployment.'Sascha Rissel, CEO & Founder of mAInthink GmbH DeepAnT Performance- Technology from Worms for the world With the development of this high-performance technology, from Worms is positioning itself as a global pacesetter in the field of intelligent anomaly detection – a key technology for fraud detection (internet fraud), IT security, predictive analytics, financial management, and next-generation intensive patient monitoring (healthcare).
Miami Herald
03-07-2025
- Miami Herald
Science seek to tap amazing healing powers of the mouth's interior
ST. PAUL, Minn., July 2 (UPI) -- The cellular action that enables the mouth's interior lining to heal quicky and without scarring has always been a mystery but a new study suggests it may be linked to a specific "signaling pathway." That new knowledge is raising hopes the mouth lining's healing powers could be applied to other skin wounds, which take far longer to heal and often leave permanent, unsightly scars, according to a preclinical study published Wednesday by Cedars-Sinai Medical Center and University of California-San Francisco researchers. The study on mice provides evidence that the "Gas6/AXL" protein/enzyme signaling pathway is likely responsible for the mouth's amazing ability to heal itself completely from even deep bite wounds within a matter of days with no leftover scarring, the authors wrote in the journal Science Translational Medicine. Known as the oral mucosa, the mouth's interior lining heals fast and cleanly, even though it is continuously exposed to different types of microbes, abrasion from foods, motion and tension. This unique regenerative capacity is made possible by specialized gene programs activated during injury, but just how those mechanisms work has been unknown. In the study reported Wednesday, a research team led by Dr. Ophir Klein, executive vice dean of Children's Health at Cedars-Sinai and executive director of Cedars-Sinai Guerin Children's in Los Angeles, found that by manipulating levels of the AXL enzyme they could affect how wounds healed. For instance, if they inhibited AXL in mice, the healing of oral mucosa wounds worsened, making them more like skin wounds. Conversely, when they stimulated AXL in facial skin wounds, they healed more efficiently and with reduced scarring, much like the oral mucosa. Boosting the levels of AXL suppresses the expression of another protein called Focal Adhesion Kinase, or FAK, which plays a significant role in scar formation during wound healing. Should future research validate the benefits for humans, the new knowledge could aid in developing new therapies to heal skin wounds with reduced scarring, Klein said. "We are actively thinking about harnessing AXL-driven repair in both the mouth and the skin, and perhaps in other tissues as well," he told UPI in emailed comments. "One application that comes to mind is to improve healing and reduce scarring in the skin for burn victims or those with other cutaneous disorders. "Another is that there are a number of diseases of the mouth, many of them autoimmune, in which severe oral ulcers form and heal poorly or not at all. These are different from canker sores, also known as aphthous ulcers, which many people get and which typically heal on their own; the more severe ulcers are difficult to treat and cause very significant illnesses, and we currently do not have good therapies for them." A related direction for research could focus on "obtaining a deeper understanding of the effects of AXL signaling on scarring and regeneration at a molecular level, in terms of other components of the signaling pathways," Klein added. "It will also be interesting to explore the role of this pathway in other tissues and organs, and in the context of distinct injuries and perturbations --for example, physical cuts vs heat burns vs irradiation versus chemical insults." Meanwhile, a pair of recent animal studies led by the University of Arizona in Tucson similarly have shown that the use of FAK inhibitors can make skin grafts look more like healthy skin and produce less scarring, raising hopes for a potential new treatment for survivors of blast wounds, burns and other major injuries. Kellen Chen, an assistant research professor in the university's Department of Surgery and lead author of those papers, said the current Cedars-Sinai study appears to add to a mounting list of evidence that "FAK acts as a central mediator of scarring in the oral mucosa gives additional credence to the importance of this factor." Chen was not involved with the new study. "A better understanding of how the oral mucosa heals without scarring through the FAK pathway will allow us to better develop therapies to target FAK for healing in the future," he told UPI. Chen said his team has the funding to pursue Food and Drug Administration approval for a FAK inhibitor, or FAKI, hydrogel therapy and expects to conduct human trials soon. The growing evidence that wound healing can be accelerated at the cellular level "could have strong clinical implications for the treatment of severe injuries for humans and animals, especially because there are zero FDA-approved treatments that reduce scar formation," he added. "Patients with severe injuries or burns can suffer a lifetime of pain and disfigurement from scarring. The potential to heal burn injuries with regeneration, rather than scarring, would dramatically change the lives of these patients." Copyright 2025 UPI News Corporation. All Rights Reserved.
UPI
02-07-2025
- UPI
Science seek to tap amazing healing powers of the mouth's interior
1 of 2 | The amazing ability of the mouth's lining to quickly heal itself without scarring is likely due to a specific cellular action that could be applied to skin wounds sustained elsewhere on the body, according to a study released Wednesday. File Photo by Molly Riley/UPI | License Photo ST. PAUL, Minn., July 2 (UPI) -- The cellular action that enables the mouth's interior lining to heal quicky and without scarring has always been a mystery but a new study suggests it may be linked to a specific "signaling pathway." That new knowledge is raising hopes the mouth lining's healing powers could be applied to other skin wounds, which take far longer to heal and often leave permanent, unsightly scars, according to a preclinical study published Wednesday by Cedars-Sinai Medical Center and University of California-San Francisco researchers. The study on mice provides evidence that the "Gas6/AXL" protein/enzyme signaling pathway is likely responsible for the mouth's amazing ability to heal itself completely from even deep bite wounds within a matter of days with no leftover scarring, the authors wrote in the journal Science Translational Medicine. Known as the oral mucosa, the mouth's interior lining heals fast and cleanly, even though it is continuously exposed to different types of microbes, abrasion from foods, motion and tension. This unique regenerative capacity is made possible by specialized gene programs activated during injury, but just how those mechanisms work has been unknown. In the study reported Wednesday, a research team led by Dr. Ophir Klein, executive vice dean of Children's Health at Cedars-Sinai and executive director of Cedars-Sinai Guerin Children's in Los Angeles, found that by manipulating levels of the AXL enzyme they could affect how wounds healed. For instance, if they inhibited AXL in mice, the healing of oral mucosa wounds worsened, making them more like skin wounds. Conversely, when they stimulated AXL in facial skin wounds, they healed more efficiently and with reduced scarring, much like the oral mucosa. Boosting the levels of AXL suppresses the expression of another protein called Focal Adhesion Kinase, or FAK, which plays a significant role in scar formation during wound healing. Should future research validate the benefits for humans, the new knowledge could aid in developing new therapies to heal skin wounds with reduced scarring, Klein said. "We are actively thinking about harnessing AXL-driven repair in both the mouth and the skin, and perhaps in other tissues as well," he told UPI in emailed comments. "One application that comes to mind is to improve healing and reduce scarring in the skin for burn victims or those with other cutaneous disorders. "Another is that there are a number of diseases of the mouth, many of them autoimmune, in which severe oral ulcers form and heal poorly or not at all. These are different from canker sores, also known as aphthous ulcers, which many people get and which typically heal on their own; the more severe ulcers are difficult to treat and cause very significant illnesses, and we currently do not have good therapies for them." A related direction for research could focus on "obtaining a deeper understanding of the effects of AXL signaling on scarring and regeneration at a molecular level, in terms of other components of the signaling pathways," Klein added. "It will also be interesting to explore the role of this pathway in other tissues and organs, and in the context of distinct injuries and perturbations --for example, physical cuts vs heat burns vs irradiation versus chemical insults." Meanwhile, a pair of recent animal studies led by the University of Arizona in Tucson similarly have shown that the use of FAK inhibitors can make skin grafts look more like healthy skin and produce less scarring, raising hopes for a potential new treatment for survivors of blast wounds, burns and other major injuries. Kellen Chen, an assistant research professor in the university's Department of Surgery and lead author of those papers, said the current Cedars-Sinai study appears to add to a mounting list of evidence that "FAK acts as a central mediator of scarring in the oral mucosa gives additional credence to the importance of this factor." Chen was not involved with the new study. "A better understanding of how the oral mucosa heals without scarring through the FAK pathway will allow us to better develop therapies to target FAK for healing in the future," he told UPI. Chen said his team has the funding to pursue Food and Drug Administration approval for a FAK inhibitor, or FAKI, hydrogel therapy and expects to conduct human trials soon. The growing evidence that wound healing can be accelerated at the cellular level "could have strong clinical implications for the treatment of severe injuries for humans and animals, especially because there are zero FDA-approved treatments that reduce scar formation," he added. "Patients with severe injuries or burns can suffer a lifetime of pain and disfigurement from scarring. The potential to heal burn injuries with regeneration, rather than scarring, would dramatically change the lives of these patients."
